WAVE Life Sciences (NASDAQ:WVE) highlighted positive interim data from the ongoing Phase 1 INLIGHT trial of WVE-007, a GalNAc-siRNA designed to treat obesity by improving body composition through fat loss—particularly visceral fat—while preserving muscle. Company executives emphasized durable target engagement, a favorable safety profile, and early signals of clinically meaningful changes in body composition following a single dose in otherwise healthy individuals with overweight or class 1 obesity.
Mechanism and differentiation: targeting inhibin E to lower Activin E
Chief Scientific Officer Dr. Erik Ingelsson described WVE-007 as an “orthogonal” approach to current obesity therapies such as GLP-1s and other incretins, which primarily drive weight loss through caloric restriction and can be associated with muscle loss, frequent dosing, and tolerability issues. WVE-007 is designed to silence inhibin E (INHBE) in the liver, reducing circulating Activin E. The company described Activin E as a hepatokine that binds to the ALK7 receptor on adipocytes and “blocks adipose lipolysis,” promoting fat storage.
Wave said it selected inhibin E silencing over direct ALK7 targeting for efficiency and durability (via GalNAc-siRNA delivery to hepatocytes) and for selectivity, noting ALK7 has multiple ligands across tissues.
Phase 1 INLIGHT design and patient population
Chief Medical Officer Dr. Chris Wright outlined that the Phase 1 portion of INLIGHT is a placebo-controlled, single ascending dose study randomized 3:1 active to placebo. It is designed primarily to assess safety, tolerability, pharmacokinetics, and pharmacodynamics (Activin E levels), with exploratory endpoints including body composition by DEXA, biomarkers, and body weight. Key inclusion criteria include HbA1c < 5.9 and BMI 28–35, and the study does not require diet or exercise modification or counseling.
The company has tested doses including 75 mg (subtherapeutic, without DEXA), and 240 mg, 400 mg, and 600 mg cohorts (with DEXA in the latter cohorts). The update focused primarily on six-month follow-up from the 240 mg cohort and observations from the 400 mg cohort, along with safety and PK updates across the 75–600 mg range.
Wright noted baseline differences between cohorts: the 400 mg cohort had lower baseline BMI, waist circumference, body weight, total fat, and visceral fat and higher lean mass compared with the 240 mg cohort, with visceral fat about 30% lower in the 400 mg group.
Interim results: durable Activin E suppression and body composition changes
Wave reported a “very clean” safety profile across cohorts. Management said there were no treatment discontinuations, no serious treatment-emergent adverse events, and no deaths, and all study-related adverse events were mild. Wright added there were no clinically meaningful changes in lipids, glucose, or other lab measures, including liver function tests, through 600 mg.
On pharmacodynamics, the company reported “highly statistically significant,” dose-dependent Activin E reductions across dose levels, with a mean maximum reduction of up to 88%. Wave also reported that over 70% suppression was observed out to at least seven months, which executives said supports potential once- or twice-yearly dosing.
For the 240 mg cohort, the company highlighted progressive improvements in body composition over time after a single subcutaneous dose:
- Visceral fat mass: placebo-adjusted reduction improved from 7.8% at three months to 14.3% at six months (statistically significant at six months).
- Total fat: placebo-adjusted reduction of 5.3% at six months.
- Lean mass: described as stabilized.
- Waist circumference: 3.3% reduction at six months.
- Body weight: 0.9% reduction at six months (Wright also characterized weight loss as about 1%).
Wright and Ingelsson also discussed the visceral fat-to-muscle ratio (VMR) as a composite body composition metric integrating reductions in harmful visceral fat and preservation of lean mass. Wave presented an internal benchmarking analysis comparing the 240 mg single-dose VMR change in INLIGHT with estimated VMR changes for treatment arms in the Phase 2 BELIEVE study (weekly semaglutide and IV bimagrumab). Wright said the single 240 mg dose of WVE-007 “outperform[ed]” high- and low-dose semaglutide on VMR at three and six months, attributing this to semaglutide-associated lean mass reductions, and said WVE-007’s VMR improvement was “on par with bimagrumab,” while potentially enabling once-yearly dosing.
Response drivers and Phase 2a plans
In the 400 mg cohort, Wave said placebo-adjusted changes at three months were lower than in the 240 mg cohort (for example, a 5% visceral fat reduction). Management attributed the difference to the 400 mg cohort’s healthier baseline body composition. In a post-hoc analysis stratifying participants by baseline visceral fat above or below 500 g (described as a threshold for healthy visceral fat levels), the company said it observed similar statistically significant visceral fat reductions at three months in participants with baseline visceral fat >500 g across cohorts. Executives said this supports the view that baseline BMI and excess visceral fat drive response magnitude.
Wave said it is preparing the Phase 2a portion of INLIGHT, a multiple-dose amendment expected to initiate in Q2 2026. The Phase 2a study is expected to enroll individuals with BMI 35–50 and comorbidities, with 3:1 active-to-placebo randomization. It will include two populations (with and without type 2 diabetes), with the diabetic cohort starting after the first two high-BMI cohorts. Participants are planned to receive two doses at day 1 and day 85, with 12 months of follow-up and a major assessment at day 85.
Endpoints and assessments are expected to include body composition by MRI, liver fat by MRI-PDFF, HbA1c, lipid levels, CRP, and muscle function. Executives said these readouts could help inform development in additional indications including MASH, type 2 diabetes, and cardiovascular disease.
On dosing strategy, management said dose selection for Phase 2a is informed primarily by Activin E suppression and safety. The company said the 240 mg and 400 mg doses are expected to keep suppression below a targeted ~70%–75% threshold, while longer-duration data will inform whether dosing can be once yearly or twice yearly. Management said Phase 2a dose selection was not informed by efficacy observations from the 600 mg cohort, with additional 600 mg data planned to be shared later.
Other milestones and financial position
CEO Dr. Paul Bolno said Wave ended the year with over $600 million in cash and cash equivalents and characterized the company as well-capitalized. Beyond WVE-007, he noted WVE-006 is expected to deliver data from the 400 mg multi-dose cohort and the 600 mg single-dose cohort of RestorAATion-2 at the ATS conference in May, and the company expects regulatory feedback in mid-2026 on a potential accelerated approval pathway.
Wave also said it remains on track to initiate additional clinical trials investigating WVE-007 as an incretin add-on and as a post-incretin maintenance therapy in 2026.
About WAVE Life Sciences (NASDAQ:WVE)
WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.
The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.
